# Lunit and Summit Test AI Pathology for Ivonescimab Research

> Lunit and Summit Therapeutics are using AI pathology to analyze tumor images in ivonescimab research.

- Type: AI news
- Page: https://completeaitraining.com/news/lunit-and-summit-test-ai-pathology-for-ivonescimab-research/
- Published: 2026-10-25
- Updated: 2026-10-24
- Author: Jeroen Erne
- Jobs: Healthcare, Product development, Science and research
- Reading time: 1 min

Lunit and Summit Therapeutics are collaborating to apply artificial intelligence pathology in the analysis of tumor images as part of research involving ivonescimab. The effort centers on using AI-driven image models to examine tissue samples within the drug’s development program.

The partnership reflects a broader trend in which image-based AI models are being integrated directly into evidence-generation workflows for drug development. By incorporating computational pathology, the companies aim to support the research process for ivonescimab through advanced image analysis.

---

This is the Markdown form of https://completeaitraining.com/news/lunit-and-summit-test-ai-pathology-for-ivonescimab-research/. The whole site is mapped at https://completeaitraining.com/llms.txt.